Duchene’s muscular dystrophy: a clinical case

Authors

DOI:

https://doi.org/10.26641/1997-9665.2026.1.48-53

Keywords:

Duchene's muscular dystrophy, genetic mutation, pulmonary-heart failure

Abstract

Background. Muscular dystrophy is a heterogeneous group of genetic disorders characterized by progressive loss of skeletal muscles. Duchene's muscular dystrophy (MDD) is one of the most common and pronounced forms of muscular dystrophy associated with the X chromosome on a recessive feature and belongs to the class “Dystrofinopathy”. Dystrophinopathy develops in the hereditary absence of a membrane protein of dystrophin, which is responsible for the integrity of the muscle cell cytoskeleton. MDD develops quite slowly and is asymptomatic at an early stage. In the subsequent course of the disease there are severe lesions of skeletal and respiratory muscles, heart, delayed psycho -language development and organic lesions of the nervous system. Multiple insufficiency in such patients causes high rates of early mortality. Aim. The purpose of the work is to describe a clinical case of a rare Duchene muscle dystrophy disease with a patient who was treated with a regional clinical hospital with a more detailed study of pathomorphological changes in this pathology. Methods. The material for the study was a clinical case of Duchene's muscular dystrophy in a patient who died in the Emergency Medical Assistance Department of the KNP Choir "Regional Clinical Hospital" in Kharkiv with a clinical diagnosis: Duchene's muscular dystrophy. The patient's medical history and the autopsy protocol were studied. Histological examination was performed using the following painting methods: hematoxylin-eosin, van Gizon, Congo red, Perls reaction. Results. Autopsy revealed the following pathomorphological changes: lesions of skeletal muscles - scoliosis, pseudogipertrophy of the calf muscles; respiratory damage and cardiomyopathy pathology, which have led to the development of decompensated right ventricular heart failure in the patient. Conclusion. MDD is a rare progressive disease that is inherited with dystrophin protein deficiency. Pathology occurs in early childhood and leads to muscle tissue. Most patients die from pulmonary - heart failure. In this case, the pathomorphological changes that occur in this disease are described.

References

  1. Chien Y, Lee N, Weng W, Chen L, Huang Y, Wu C, Hwu W. Duchenne muscular dystrophy newborn screening: the first 50,000 newborns screened in Taiwan. Neurological Sciences. 2022;43:4563–6. doi: 10.1007/s10072-022-06128-2.
  2. Jia X, Jiang X, Huang Y. A pilot study of newborn screening for Duchenne muscular dystrophy in Guangzhou. Heliyon. 2022;8(10):e11071 doi: 10.1016/j.heliyon.2022.e11071.
  3. Markati T, Oskoui M, Farrar MA, Duong T, Goemans N, Servais L. Emerging therapies for Duchenne muscular dystrophy. The Lancet Neurology. 2022;21(9):814-29. doi: 10.1016/S1474-4422(22)00125-9.
  4. Liaqat ST, Akram F, Waseem R, Akram A, Altaf M Z, Haider B, Arif A. Overview of muscular dystrophy, it’s types, symptoms, management and possible treatment. Pure and Applied Biology. 2023; 12(1):261-73. doi: 10.19045/bspab.2023.120028.
  5. Venugopal V, Pavlakis S. Duchenne Muscular Dystrophy. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. 2025. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482 346/
  6. Kirillova LG, Bubryak МE, Miroshnikov AA, Yuzva AA. Duchenne muscular dystrophy: problems of differential diagnosis and treatment. Ukrainian Journal of Perinatology and Pediatrics. 2020;1(81):106-11. doi: 10.15574/PP.2020.81.106.
  7. Mair D, Biskup S, Kress W, Abicht A, Brück W, Zechel S, Knop KC, Koenig FB, Tey S, Nikolin S, Eggermann K, Kurth I, Ferbert A, Weis J. Differential diagnosis of vacuolar myopathies in the NGS era. Brain Pathology. 2020;30(5):877-96. doi: 10.1111/bpa.12864.
  8. Leckie J, Zia A, Yokota T. An Updated Analysis of Exon-Skipping Applicability for Duchenne Muscular Dystrophy Using the UMD-DMD Database. Genes. 2024;15(11):1489. doi: 10.3390/genes15111489.
  9. Ma PP, Zhang S, Zhang H, et al. Correction to: Comprehensive genetic characteristics of dystrophinopathies in China. Orphanet J Rare Dis. 2021; 16:252. https://doi.org/10.1186/s13023-018-0853-z.
  10. Diesing J, Kirschner J, Pechmann A, König J, Kunk L, Garcia TB, Schwedhelm C, Hänsel I, Kisser A. Epidemiology, disease burden and costs of Duchenne muscular dystrophy in Germany: an observational, retrospective health claims data analysis. Orphanet Journal of Rare Diseases. 2025;20:429. doi: 10.1186/s13023-025-03906-x.
  11. Montagna С, Maiani E, Pieroni L, Consalvi S. Duchenne Muscular Dystrophy: Integrating Current Clinical Practice with Future Therapeutic and Diagnostic Horizons. Int. J. Mol. Sci. 2025; 26(14): 6742. doi: 10.3390/ijms26146742.
  12. Fortunato F, Rossi R, Falzarano MS, Ferlini A. Innovative Therapeutic Approaches for Duchenne Muscular Dystrophy. J. Clin. Med. 2021;10(4),820. doi: 10.3390/jcm10040820.
  13. Jumah MA, Muhaizea MA. et al. Current managementof Duchenne muscular dystrophy in the Middle East: expert report. Neurodegener Dis Manag. 2019;9(3):123-133. doi: 10.2217/nmt-2019-0002.
  14. Venugopal V, Pavlakis S. Duchenne Muscular Dystrophy. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. 2025. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482 346/
  15. Zhang T, Kong X. Recent advances of glucocorticoids in the treatment of Duchenne muscular dystrophy (Review). Experimental and Therapeutic Medicine. 2021;21(5):447. doi: 10.3892/etm.2021.9875.
  16. Cui Y, Shao S, Zhang L, Wu J, Ma F, Cai X, Zhou K, Wang C. The effects of glucocorticoids on cardiac function of patients with Duchenne muscular dystrophy: benefit or not? European Journal of Pediatrics. 2025;184:313. doi; 10.1007/s00431-025-06141-5.
  17. Marcì M, Vaccaro P, Polizzi V, Crescimanno G. Cardiomyopathy in Non-Ambulatory Patients with Duchenne Muscular Dystrophy: Two Case Reports with Varying Outcomes, Considering Novel Treatments. Reports. 2025;8(1):2. doi: 10.3390/reports8010002.
  18. Tizzoni F, Canella G, Fave AD, Lernia DD, Lorusso MM, Nobile M. Living with Duchenne Muscular Dystrophy Beyond the Physical Implications: Cognitive Features, Psychopathology Aspects, and Psychosocial Resources – A Narrative Review. Brain Sci. 2025;15(7):695. doi: 10.3390/brainsci15070695.
  19. Cha J, Kim I, Kim J, Choi E, Min P, Yoon YW, Lee BK, Hong B, Kwon H, Cho HE, Choi WA, Kang S, Rim S. The association between cardiac involvement and long-term clinical outcomes in patients with Duchenne muscular dystrophy. ESC Heart Failure. 2022;9:2199–206. doi: 10.1002/ehf2.13970.
  20. Landfeldt E, Ferizovićb N, Bueschc K. Timing of Clinical Interventions in Patients With Duchenne Muscular Dystrophy: A Systematic Review and Grading of Evidence. J Neuromuscular Diseases. 2022;9(3):353-64. doi: 10.3233/JND-220804.
  21. Yaru C, Shuran S, Linling Z, Jiangping W, Fan M, Xiaotang C, Kaiyu Z, Chuan W. The effects of glucocorticoids on cardiac function of patients with Duchenne muscular dystrophy: benefit or not? European Journal of Pediatrics. 2025;184:313 doi: 10.1007/s00431-025-06141-5.
  22. Diesing J, Kirschner J, Pechmann A, König J, Kunk L, Garcia TB, Schwedhelm C, Hänsel I, Kisser A. Epidemiology, disease burden and costs of Duchenne muscular dystrophy in Germany: an observational, retrospective health claims data analysis. Orphanet Journal of Rare Diseases. 2025;20:429. doi: 10.1186/s13023-025-03906-x.
  23. Soslow JH, Xu M, Slaughter JC, Crum K, Kaslow JA, George-Durrett K, Raucci Jr FJ, Wilkinson JD, Cripe LH, Hor KN, Spurney CF, Markham LW. Cardiovascular Measures of All-Cause Mortality in Duchenne Muscular Dystrophy. Circulation: Heart Failure. 2023;16(8):e010040 doi: 10.1161/CIRCHEARTFAILURE.122.010040.
  24. Orr JE., Chen K., Vaida F. et al. Effectiveness of long-term noninvasive ventilation measured by remote monitoring in neuromuscular disease. ERJ Open Res. 2023;9:00163-2023. doi: 10.1183/23120541.00163-2023.
  25. Nakaz MOZ Ukrainy № 1877 vid 06.09.2021 «Pro zatverdzhennia Poriadku provedennia patolohoanatomichnykh roztyniv» [For approval of the Procedure for conducting pathological anatomical dissections].
  26. Ministry of Health of Ukraine. Order of the Ministry of Health of Ukraine No. 1877 dated September 06, 2021 "Pro zatverdzhennia Poriadku provedennia patolohoanatomichnykh roztyniv" [On approval of the Procedure for conducting pathological and anatomical dissections]. 2021. Ukrainian. Available from: https://zakon.rada.gov.ua/laws/show/z1239-21#Text.
  27. Suvarna SK, Layton C, Bancroft JD. Bancroft’s theory and practice of histological techniques. 8th ed. Oxford: Elsevier; 2019. 603 p. ISBN: 978-0-7020-4226-3. Available from: https://knustmeltsa. wordpress.com/wp-content/uploads/2020/08/bancrofts-theory-and-practice-of-histological-techniques-7th-edition-0702042269autosaved1.pdf
  28. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-4. doi: 10.1001/jama.2013.281053.

Downloads

Published

2026-03-27

How to Cite

Tytov , Y., Romaiev, S., Yakovtsova , I., Zagrebelska , A., Antonov , A., Kiriya , D., & Kozachenko , I. (2026). Duchene’s muscular dystrophy: a clinical case. Морфологія / Morphologia / Morfologìâ, 20(1), 48–53. https://doi.org/10.26641/1997-9665.2026.1.48-53

Issue

Vol. 20 No. 1 (2026)

Section

Статті

License

Copyright (c) 2026 Author, Morphologia

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

 The authors reserve the right to authorship of their work and transfer to the Journal the right to the first publication of this work under the terms of a license Creative commons Attribution 4.0 International (CC BY 4.0), which allows other people to freely distribute the published work with a mandatory reference to the authors of the original work and the first publication of the work in this journal.
        By submitting a manuscript to the editorial office of the Journal ‘Morphologia’ authors agree to transfer the rights to protect and use the manuscript (all supplemental materials, particularly protected objects such as photos, drawings, diagrams, tables, etc.), including the reproduction in the press and distribution via the Internet; translation of the manuscript into any language; export and import of journal copies with the Authors’ article in order to make it available for public. Authors convey the rights mentioned above to the editorial office without any temporal or territorial limitation all over the world. 
        The Authors guarantee that they have the exclusive rights to use the material transferred to editorial office. Editors are not responsible to third parties for contraventions of warranty given by the Authors. The considered rights are transferred to the editorial office since the moment when the current issue is signed for publishing. Reproduction of materials published in the Journal by other individuals and legal entities is possible only with the consent of Editorial office, with the obligatory indication of the full bibliographic reference of the primary publication. The Authors reserve the right to use the published material, its fragments and parts for teaching materials, oral presentations, dissertation thesis prepararion with obligatory bibliographic citation of the original paper. Electron copy of the published article, downloaded from official journal web-site in .pdf format may be put by authors on the official web-site of their institutions, any other official resources with open access.